Chemomab Therapeutics (CMMB) Net Income Growth (1y) (2018 - 2025)
Chemomab Therapeutics (CMMB) Net Income Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 63.48% |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | - |
| 10 | Chemomab Therapeutics | 719.42 Mn | 709.06 Mn | - | 65.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 65.90% |
| Sep 30, 2025 | -49.99% |
| Dec 31, 2024 | 11,036,839.42% |
| Sep 30, 2024 | 109.28% |
| Jun 30, 2024 | -54.05% |
| Mar 31, 2024 | -55.60% |
| Dec 31, 2023 | -58.59% |
| Sep 30, 2023 | -22.37% |
| Jun 30, 2023 | 8.57% |
| Mar 31, 2023 | 270.67% |
| Dec 31, 2022 | 263.86% |
| Sep 30, 2022 | -933.29% |
| Jun 30, 2022 | 362.74% |
| Mar 31, 2022 | -199.53% |
| Dec 31, 2021 | 21.12% |
| Sep 30, 2021 | -21.19% |
| Jun 30, 2021 | -156.24% |
| Mar 31, 2021 | -0.53% |
| Dec 31, 2020 | 89.94% |
| Sep 30, 2020 | 84.61% |